FDA Ends First Half Of 2003 With 9 NME, 6 BLA Approvals
This article was originally published in Pharmaceutical Approvals Monthly
FDA closed out the first half of 2003 with nine new molecular entities and six major biologic approvals, putting the agency well ahead of where it was at the same time last year.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011